Disease relevance of Showdomycin

• Showdomycin and its reactive moiety, maleimide. A comparison in selective toxicity and mechanism of action in vitro [1].
• Intracellularly, in mouse lymphoma cells (L5178y), showdomycin is phosphorylated to showdomycintriphosphate, via the mono- and diphosphate stage [2].
• Cytotoxicities of cytosine arabinoside (Ara C) and showdomycin to murine L1210 leukemia cells was prevented by a nucleoside transport inhibitor, cimicifugoside [3].

High impact information on Showdomycin

• Glycolipid formation in Volvox carteri f. nagariensis: effects of tunicamycin and showdomycin [4].
• Pretreatment of neutrophils by showdomycin, a very slowly penetrating-SH reagent, did not affect superoxide production by all of the stimuli used, suggesting no exposure of sulfhydryl groups involved in superoxide-generating system on the cell surface [5].
• 5. The antibiotic showdomycin strongly inhibits the attachment of EF-1 to ribosomes and to a lesser degree impairs the binding of EF-2 [6].
• Base-pairing studies employing high resolution NMR spectroscopy indicate that both showdomycin and epishowdomycin base-pair with adenosine-5'-monophosphate (AMP); however, while showdomycin also shows evidence of stacking, that was absent in epishowdomycin [7].
• Degradation and intracellular phosphorylation of showdomycin [2].

Biological context of Showdomycin

• Molecular modeling studies using QUANTA/CHARMm show that showdomycin is capable of forming a homopolymer duplex by base-pairing with poly(A), but with a considerably broader and deeper major groove [7].
• Showdomycin inhibited pig brain (Na+ + K+)-ATPase with pseudo first-order kinetics [8].

References